Gene
DNMT3A
DNMT3A is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (18), Actionable biomarkers (1), Trial mentions (28), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention DNMT3A. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 22 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 4 of 8,738 | 0.05% | not measured | |
| 2025 | 3 of 8,875 | 0.03% | not measured | |
| 2024 | 5 of 8,597 | 0.06% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 44 of 11,460 | 0.38% |
| 2022 | 1 of 8,285 | 0.01% | 57 of 13,598 | 0.42% |
| 2021 | 2 of 8,692 | 0.02% | 63 of 15,045 | 0.42% |
| 2020 | 0 of 7,640 | 0.00% | 36 of 14,459 | 0.25% |
| 2019 | 3 of 7,300 | 0.04% | 41 of 12,159 | 0.34% |
| 2018 | 3 of 6,927 | 0.04% | 40 of 11,854 | 0.34% |
| 2017 | 1 of 6,558 | 0.02% | 31 of 11,595 | 0.27% |
Showing 10 of 37 years.
Assay-provider ledger (18)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Agilent | Reagent supplier | Clinical validation | 2 | August 13, 2025 |
| Illumina | Unclassified | Clinical validationAnalytical validation | 7 | August 13, 2025 |
| QIAGEN | Reagent supplier | Clinical validationAnalytical validation | 6 | August 13, 2025 |
| Acornmed Biotechnology | Diagnostic provider | Clinical validation | 1 | December 17, 2024 |
| Geisinger | Not a company | Clinical validation | 1 | September 01, 2021 |
Showing 5 of 18 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| DNMT3A oncogenic mutation | Daunorubicin | response-associated | acute myeloid leukemia | Cancer Genome Interpreter |
Trial mentions (28)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT02823210 | Trial biospecimen (AACT) |
| NCT04100876 | Trial biospecimen (AACT) |
| NCT05250362 | Trial eligibility (AACT) |
| NCT06768476 | Trial eligibility (AACT) |
| NCT02497404 | Trial eligibility (AACT) |
Showing 5 of 28 trial mentions.
Target-disease associations (688)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Abnormality of the nervous system | phenotype | Variant curation (ClinVar / EVA) |
| Absence of circulating granulocytes | phenotype | gene burden |
| Absence of circulating granulocytes | phenotype | GWAS credible sets |
| Acute Leukemia | cancer or benign tumor | Literature (Europe PMC) |
| Adenoid Cystic Breast Carcinoma | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 688 associations.
Vendor sourcing (106)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | Canonical splice site: predicted to alter splicing and result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or pro... | View ClinVar record SCV002011942.1 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV007333689.1 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.2645G>A (p.R882H) alteration is located in exon 23 (coding exon 22) of the DNMT3A gene. This alteration results from a G to A substitution at nucleotid... | View ClinVar record SCV000740689.5 |
| Assistance Publique – Hôpitaux de Paris | Trial sponsor | Biospecimen collected in a trialTrial biospecimen collection | No supporting text recorded; see the citation. | View trial NCT02823210 |
| Assistance Publique – Hôpitaux de Paris | Trial sponsor | Mentioned in trial textTrial free-text mention | DNMT3A | View trial NCT02823210 |
Showing 5 of 106 sourcing records.
Trial-cited literature (474)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Dual FLT3/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trial. | Blood neoplasia | 2026 | 2 |
| Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study. | American journal of hematology | 2026 | 0 |
| Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab. | Journal of hematology & oncology | 2025 | 22 |
| Clonal Hematopoiesis and Cardiovascular Outcomes in Older Women. | Journal of the American College of Cardiology | 2025 | 18 |
| Characterization and treatment outcomes of malignant histiocytoses in a retrospective series of 141 cases in France. | Blood advances | 2025 | 13 |
Showing 5 of 474 papers.
Protein variant mentions (40)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A248S | 1 | 2011 | PMID 21995386 |
| p.D58V | 1 | 2011 | PMID 21995386 |
| p.E1610V | 1 | 2011 | PMID 21995386 |
| p.E40D | 1 | 2015 | PMID 25741868 |
| p.E545G | 1 | 2015 | PMID 25741868 |
Showing 5 of 40 variants.
Literature-extracted relations (73)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Pyridoxal Phosphate | Chemical | associate |
Associations between Genetic Variants and Blood Biomarkers of One-Carbon Metabolism in Postmenopausal Women from the Women's Health Initiative Observational Study. | 2022 |
| HYDROXYUREA | Chemical | negative_correlate |
Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses. | 2022 |
| AZACITIDINE (VIDAZA) | Chemical | negative_correlate |
The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial. | 2021 |
| Tretinoin | Chemical | associate |
Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells. | 2017 |
| Ascorbic Acid | Chemical | associate |
Epigenetics of CD4+ T cells in autoimmune diseases. | 2017 |
Showing 5 of 73 relation assertions.
Organizations publishing (473)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| The University of Texas System | Academic | 35 | 2012 to 2026 |
| Memorial Sloan Kettering Cancer Center | Hospital | 30 | 2012 to 2023 |
| Dana-Farber Cancer Institute | Other | 26 | 2014 to 2023 |
| Harvard Medical School | Academic | 24 | 2014 to 2025 |
| Mass General Brigham | Hospital | 19 | 2014 to 2025 |
Showing 5 of 473 organizations.
Where DNMT3A appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of ear
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- measurement
- medical procedure
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
547 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.